Invesco Exchange-Traded Self-Indexed Fund Trust has released its latest financial report, detailing its assets and liabilities as of August 31, 2026. This report is significant as it provides insights into the fund's performance and its strategic positioning within the investment industry.
According to the filing, the fund's total assets stand at approximately $53.5 million, with total liabilities of about $3.1 million. The net assets are reported at approximately $50.4 million, indicating a solid financial foundation for the fund.
Background
Invesco Exchange-Traded Self-Indexed Fund Trust, with a Central Index Key (CIK) of 0001657201, operates as an investment entity. The fund was previously known as PowerShares Exchange-Traded Self-Indexed Fund Trust, a name it adopted following a change in 2015. The trust is based in Downers Grove, Illinois, and is registered under SEC file number 811-23304.
What the Filing Says
The recent filing, accession number 0001657201-26-000781, highlights the fund's financial metrics as of August 31, 2026. It states, "The total assets are $53,496,348.14, and total liabilities are $3,067,148.98, resulting in net assets of $50,429,199.16." This data underscores the fund's financial health and operational capabilities.
Impact
The financial report impacts various stakeholders, including investors, analysts, and competitors in the investment sector. The detailed breakdown of assets and liabilities allows investors to gauge the fund's performance and make informed decisions. Competitors in the investment industry must also consider these figures as they strategize to maintain or improve their market positions.
What's Next
The filing does not say what happens next. However, stakeholders will likely be monitoring future reports for additional insights into the fund's performance and strategic initiatives.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






